CAR-T cell therapy followed by allogenic hematopoietic stem cell transplantation yielded comparable outcome between Ph like ALL and other high-risk ALL

Dai, Hai-ping; Kong, Dan-qing; Shen, Hong-jie; Cui, Wei; Wang, Qian; Li, Zheng; Yin, Jia; Kang, Li-qing; Yu, Lei; Wu, De-pei; Tang, Xiao-wen

doi:10.1186/s40364-023-00451-2

Table 1 Clinical and laboratory data of all Ph-like patients

From: CAR-T cell therapy followed by allogenic hematopoietic stem cell transplantation yielded comparable outcome between Ph like ALL and other high-risk ALL

No.	Gender	Age	WBC ×10⁹/L	Karyotype	FISH	Fusion gene by RNA-Seq	DNA-NGS	Targeted drugs	Response to targeted drugs	CART Target	Status before CART	Best response to CART	HSCT type	Relapse post CART	Outcome
1	M	6	44.9	46,XY,t(8;17) (p11;q11) [20]	Neg	NCOR1::LYN	ARID1A A41V, KRAS G12A, NRAS Q61H, PAX5 R140L, STAT5A A217H, ZNF292 Asn1695del	dasatinib	sensitive	Tandem CD19/CD22	CR2 MRD+	CR MRD+	haplo	Y	Alive
2	M	18	145.0	NK	ND	NUP214::ABL1	Neg	no	NA	CD19	CR1 MRD+	CR MRD-	haplo	N	Alive
3	F	15	14.8	NK	ABL1r	FOXP1::ABL1	KMT2C A878V	dasatinib	sensitive	CD19	CR1 MRD+	CR MRD-	haplo	Y	Dead
4	M	39	47.3	NK	PDGFRBr	EBF1::PDGFRB	Neg	dasatinib	insensitive	Tandem CD19/CD22	active disease	CR MRD-	haplo	N	Alive
5	M	14	64.3	46,XY,t(1;5) (q25;q32) [20]	ABL2r	KIAA1191::ABL2	Neg	dasatinib	insensitive	Tandem CD19/CD22	active disease	CR MRD+	haplo	N	Alive
6	F	26	124.8	NK	PDGFRBr	TERF2::PDGFRB	Neg	dasatinib	sensitive	CD19	CR1 MRD+	CR MRD-	haplo	N	Alive
7	M	25	5.0	NK	CRLF2r	P2RY8::CRLF2 EP300::ZNF384	CBL L370_Y371del	ruxolitinib	sensitive	Tandem CD19/CD22	CR1 MRD+	CR MRD-	haplo	N	Alive
8	F	21	55.4	NK	JAK2r	STRBP::JAK2	Neg	ruxolitinib	insensitive	Tandem CD19/CD22	active disease	CR MRD+	haplo	Y	Dead
9	M	19	2.6	NK	CRLF2r	CRLF2::IgH USP9X::DDX3X	DNMT3A A107V JAK2 R683G	ruxolitinib	insensitive	Tandem CD19/CD22	active disease	CR MRD-	haplo	Y	Dead
10	F	24	23.1	NK	CRLF2r	CRLF2::IgH	JAK2 V878M	ruxolitinib	insensitive	Tandem CD19/CD22	active disease	CR MRD-	URD	N	Alive
11	M	50	69.4	NK	CRLF2r	CRLF2::IgH	Neg	ruxolitinib	insensitive	CD19	active disease	CR MRD-	haplo	N	Alive
12	F	17	1.2	NK	JAK2r	ZBE2::JAK2	Neg	no	NA	CD19	active disease	CR MRD-	haplo	N	Alive
13	M	14	217.4	NK	JAK2r	RAEBP1::JAK2	ETV6 R309W	ruxolitinib	insensitive	CD19	active disease	CR MRD-	haplo	N	Alive
14	M	22	33.4	NK	CRLF2r	P2RY8::IGH	Neg	no	NA	Tandem CD19/CD22	active disease	NR	haplo	Y	Dead
15	M	39	54.0	NK	CRLF2r	CRLF2::IgH	FBXW7 Phe656fs,	no	NA	CD19	active disease	CR MRD+	URD	N	Alive
16	M	22	20.2	NK	CRLF2r	CRLF2::IgH	JAK2 R683G, PTPN11 A72V, CXCR4 337fs, FGFR3 A173C, MYC Y373R	ruxolitinib	insensitive	Tandem CD19/CD22	active disease	CR MRD+	haplo	N	Alive
17	M	17	1.7	45,XX,-11[10] /46,XY[10]	CRLF2r	P2RY8::IGH	ANKRD26 N267S, PTPN11 E76K	no	NA	CD19	CR1 MRD-	CR MRD-	haplo	N	Alive

Abbreviations: CR Complete remission, F Female, haplo Haploidentical, M Male, MRD Measurable residual disease, N No, NA Not applicable, ND Not done, Neg Negative, NK Normal karyotype, NR No remission, r Rearrangement, URD Unrelated donor, Y Yes

Back to article page

ISSN: 2050-7771

Contact us

General enquiries: journalsubmissions@springernature.com

Biomarker Research

Contact us